Company intelligence / Profile preview

C2 Diagnostics

St. Louis, Missouri, United States

Ownership: Private
Development stage: Other

Overview

The PrecivityAD2™ blood test achieves over 90% diagnostic accuracy for detecting amyloid pathology, a hallmark of Alzheimer's disease, with validation against cerebrospinal fluid analysis and amyloid PET imaging. The test is used in clinical care and has supported over 150 Alzheimer's disease research studies.

Therapeutic areas: Neurology
Modalities: Biomarker assay (mass spectrometry-based)Blood testLaboratory-developed test (LDT)
Industry: Protein Biomarker Diagnostics

Partnerships

Grupo FleuryHealiusMayo Clinic LaboratoriesUnilabsAccuserv Diagnostic Center (Philippines)Archerfish Precision Diagnostics (Singapore)Codex Genetics (Hong Kong)Dr. Dangs Lab (India)Medical Link (Israel)Milenia Labs (Costa Rica and Mexico)GHR Foundation

Beyond the preview

Go deeper on C2 Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C2 Diagnostics.

Explore the full profile